NOV
Novo Nordisk A/S Class B · DUS:NOV
35.62 EUR1.00 +2.89%
Novo Nordisk A/S Class B (DUS:NOV) last traded at 35.62 EUR, up 2.89% on the day. Over the past year the stock is down 19.14%. Its 52-week range is 30.26 to 54.74. It is in the Health Technology sector (Pharmaceuticals: Major).
Key statistics
Open34.83
Day range34.83 – 35.72
52-week range30.26 – 54.74
Volume3
Average volume (10 days)5
Market cap (USD)175.64 B
P/E10.19
EPS (TTM) (USD)3.99
Dividend yield4.40%
Beta (1 year)0.5779
Revenue (TTM) (USD)50.21 B
Employees68.79 K
Performance
+1.44%1 week
+5.56%1 month
−20.22%3 months
+3.96%6 months
−18.65%Year to date
−19.14%1 year
Technical rating
Buy
Daily summary of 11 oscillators and 15 moving averages. See every indicator
Analysts’ target
40.98 EUR
The average 1-year price target, +15.06% from the last price. See the forecast
Latest headlines
- Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up NextStocktwits · 02 Nov 2026
- Jobs, Midterm Elections, Apple, Palantir, McDonald's, Moderna, and More to Watch This Week — Barrons.comDow Jones Newswires · 01 Nov 2026
- Healthcare Earnings Scoreboard: 96% beat EPS estimates, 70% post Y/Y earnings growthSeeking Alpha · 31 Oct 2026
- Steve Jobs' Son Says GLP-1 Weight Loss Drugs Could Be Among Most Important Medicines Ever, With Potential Impact on CancerBenzinga · 29 Oct 2026
- Lilly's retatrutide outshines Ozempic on weight loss, blood sugar control in trialReuters · 28 Oct 2026
- Novo Nordisk Loses Court Bid Against Eli Lilly’s Weight-Loss Drug Ads — Judge Says Sales Impact Was Negligible (UPDATED)Benzinga · 28 Oct 2026
- LLY Vs NVO: Lilly’s Retatrutide Beats Novo’s Ozempic In Head-To-Head Trial — Retatrutide More Than Doubles Weight LossStocktwits · 28 Oct 2026
- Lilly's next-gen drug outshines Ozempic on weight loss, blood sugar control in trialReuters · 28 Oct 2026
Market data from TradingView’s public feed, delayed as the exchange requires. For study only, not investment advice.